bit expect
organ growth trim china worri
top-lin miss ep in-lin call china headwind
report rev y/i est
guide/consensu organ sale growth vs estimate
guid driven diagnost dx segment core growth in-lin
pki hsd guid partial off-set core growth vs est msd
guid discoveri analyt solut da segment da saw strength life
scienc cannabi weak appli market particularli analyt
instrument portfolio china result lower da core growth guid
msd prior dx strength broad-bas driven reproduct health
genom servic continu track toward pki goal fx sale
vs estimate adj gm vs estimate due euroimmun season
strength genom test lower-margin adj opm expand y/i
vs estimate driven cost save better oper leverag adj
ep in-lin guid vs estimate
trim revenue guid vs previous lower organ
growth vs prior fx headwind howev management maintain
ep guid help lower tax rate still see opm expans
guid came core growth vs est
adj ep vs estimate think lower outlook doabl
despit tougher comp pki china commentari concern although china dx
remain strong weak appli market particularli industri
environment tool due combin macro slowdown bia us
compani tender although analyt instrument player
note similar issu china expect much uplift
challeng situat china look color report
updat estim reiter neutral rate
lower revenu estimate ep estimate unchang given margin
improv reiter neutral rate po
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart waltham massachusett
found diversifi
provid scientif instrument consum
servic address basic appli
research well signific global health
safeti issu includ matern fetal health
food safeti environment monitor today
compani oper two segment
environment
diversifi provid
scientif instrument consum servic
think compani tact piec
togeth numer acquir asset sinc
form uniqu comprehens solut
custom nich market posit
portfolio transform improv
growth profil believ compani still
face near-term headwind share
like rang bound
po base ep estim in-lin compani
broader lst diagnost peer group multipl signific premium
histor multipl due improv core growth margin think
multipl appropri given on-going oper improv improv
growth profil compani
upsid risk po better expect organ sale growth margin
expans faster uptak new product capit deploy option
acquisit compani
downsid risk competit execut integr risk weaker macro
environ fx swing fund cut slower expect uptak new
product regulatori risk reiter neutral rate
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
